Robert W. Ross M.D.
Net Worth
Last updated:
What is Robert W. Ross M.D. net worth?
The estimated net worth of Dr. Robert W. Ross M.D. is at least $4,643,862 as of 1 Aug 2023. He has earned $408,462 from insider trading and has received compensation worth at least $4,235,400 in Surface Oncology, Inc..
What is the salary of Robert W. Ross M.D.?
Dr. Robert W. Ross M.D. salary is $705,900 per year as Pres, Chief Executive Officer & Director in Surface Oncology, Inc..
How old is Robert W. Ross M.D.?
Dr. Robert W. Ross M.D. is 51 years old, born in 1974.
What stocks does Robert W. Ross M.D. currently own?
As insider, Dr. Robert W. Ross M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Surface Oncology, Inc. (SURF) | Pres, Chief Executive Officer & Director | 83,193 | $0 | $0 |
What does Surface Oncology, Inc. do?
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Robert W. Ross M.D. insider trading
Surface Oncology, Inc.
Dr. Robert W. Ross M.D. has made 10 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 16,713 units of SURF stock worth $15,710 on 1 Aug 2023.
The largest trade he's ever made was exercising 33,500 units of SURF stock on 21 Jul 2021. As of 1 Aug 2023 he still owns at least 83,193 units of SURF stock.
Surface Oncology key executives
Surface Oncology, Inc. executives and other stock owners filed with the SEC:
- Dr. Robert W. Ross M.D. (51) Pres, Chief Executive Officer & Director
- Dr. Vito J. Palombella (62) Chief Scientific Officer